超声与临床评估银屑病关节炎、银屑病和纤维肌痛综合征患者的外周附着点炎：ULISSE 研究。
Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study.
机构信息
From the Azienda USL-Institute for Research and Health Care (IRCCS) di Reggio Emilia; Università di Modena e Reggio Emilia, Reggio Emilia, Italy; Division of MSK and Rheumatic Disorders, National Institute of Rehabilitation, Mexico City, Mexico; Rheumatology Unit, Università Politecnica delle Marche Ospedale C. Urbani, Jesi; Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome; Dipartimento di Medicina e Scienze della salute, Università degli studi del Molise, Campobasso; Rheumatology Research Unit, Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro, Catanzaro; Rheumatology Unit, Department of Medical Sciences, University of Ferrara; Azienda Ospedaliero-Universitaria S. Anna - Ferrara; Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua; Day Hospital of Rheumatology, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini-Centro Specialistico Ortopedico (CTO), Milan; Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples; Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia," Udine; AbbVie Srl, Rome; Department of Medicine and Surgery, University of Parma, Parma, Italy. R.M. D'Attino, G. Gualberti, and R. Merolla are employees of AbbVie and may own AbbVie stocks/options. U. di Luzio Paparatti was an employee of AbbVie and may own AbbVie stocks/options. AbbVie participated in the design, study conduct, and financial support for the study, as well as in interpretation of the data, review, and approval of the manuscript. Dr. C. Salvarani has acted as a consultant for AbbVie, MSD, Pfizer Inc, Roche, Celgene, and Novartis. Dr. W. Grassi has received honoraria and speaker fees from AbbVie, Roche, BMS, Pfizer, UCB, and MSD. Dr. M. Gutierrez has attended advisory board meetings, held scientific consultancies, and has obtained consulting fees from AbbVie, UCB Pharma, Esaote SpA, Bristol-Myers Squibb, Novartis, and Merck Sharp & Dohme.
P. Macchioni, MD, Azienda USL-IRCCS di Reggio Emilia; C. Salvarani, MD, Azienda USL-IRCCS di Reggio Emilia, and Università di Modena e Reggio Emilia; N. Possemato, MD, Azienda USL-IRCCS di Reggio Emilia; M. Gutierrez, MD, Division of MSK and Rheumatic Disorders, National Institute of Rehabilitation; W. Grassi, MD, Rheumatology Unit, Università Politecnica delle Marche Ospedale C. Urbani; S. Gasparini, MD, Rheumatology Unit, Università Politecnica delle Marche Ospedale C. Urbani; C. Perricone, MD, Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University; F.M. Perrotta, MD, Dipartimento di Medicina e Scienze della Salute, Università degli studi del Molise; R.D. Grembiale, MD, Rheumatology Research Unit, Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro; C. Bruno, MD, Rheumatology Research Unit, Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro; C. Tripolino, MD, Rheumatology Research Unit, Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro; M. Govoni, MD, Rheumatology Unit, Department of Medical Sciences, University of Ferrara, and Azienda Ospedaliero-Universitaria S. Anna; G. Ciancio, MD, Rheumatology Unit, Department of Medical Sciences, University of Ferrara, and Azienda Ospedaliero-Universitaria S. Anna; I. Farina, MD, Rheumatology Unit, Department of Medical Sciences, University of Ferrara, and Azienda Ospedaliero-Universitaria S. Anna; R. Ramonda, MD, Rheumatology Unit, Department of Medicine DIMED, University of Padua; P. Frallonardo, MD, Rheumatology Unit, Department of Medicine DIMED, University of Padua; F. Desiati, MD, Day Hospital of Rheumatology, ASST Gaetano Pini-CTO; R. Scarpa, MD, Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II; L. Costa, MD, Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II; A. Zabotti, MD, Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia"; S. De Vita, MD, Rheumatology Clinic, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia"; R.M. D'Attino, MD, AbbVie Srl; G. Gualberti, PhD, AbbVie Srl; R. Merolla, MD, AbbVie Srl; U. di Luzio Paparatti, MD, AbbVie Srl; R. Aldigeri, BSc, Department of Medicine and Surgery, University of Parma; A. Marchesoni, MD, Day Hospital of Rheumatology, ASST Gaetano Pini-CTO.
出版信息
J Rheumatol. 2019 Aug;46(8):904-911. doi: 10.3899/jrheum.171411. Epub 2019 Mar 15.
OBJECTIVE
The purpose of the ULISSE study was to evaluate the prevalence of clinical and ultrasonographic (US) entheseal involvement in patients with psoriatic arthritis (PsA), psoriasis, and fibromyalgia syndrome (FMS).
METHODS
In this cross-sectional multicenter study, patients with PsA and psoriasis (not taking systemic therapy) and FMS underwent a clinical evaluation of the entheses, and a B-mode and power Doppler examination of 6 pairs of entheses.
RESULTS
The study analyzed 140 patients with PsA, 51 with psoriasis, and 51 with FMS. Clinical and US examinations were performed in 1960 and 1680 entheses in the PsA group, and 714 and 612 entheses both in the psoriasis group and in the FMS group. In both per-patient and per-enthesis evaluation, the frequency of entheseal tenderness was higher in patients with FMS (92% of the patients and 46% of the entheses, compared with 66%/23% in the PsA group and 59%/18% in the psoriasis group). With US examination, signs of entheseal involvement were more frequent in both the per-patient and per-enthesis evaluation in PsA and psoriasis (about 90% of patients in both the PsA and psoriasis groups and 75% of patients in the FMS group had at least 1 site affected, and 54%, 41%, and 27% of the pairs of entheses in, respectively, PsA, psoriasis, and FMS patients showed at least 1 enthesis involved).
CONCLUSION
The ULISSE study indicated that enthesitis is a common feature in patients with PsA, those with psoriasis, and in those with FMS if only clinical examination is used. US entheseal assessment showed findings more consistent with the 3 disorders.
目的
ULISSE 研究旨在评估银屑病关节炎（PsA）、银屑病和纤维肌痛综合征（FMS）患者的临床和超声（US）肌腱附着处受累的患病率。
方法
在这项横断面多中心研究中，PsA 和银屑病（未接受系统治疗）以及 FMS 患者接受了肌腱附着处的临床评估，以及 6 对肌腱附着处的 B 型和功率多普勒检查。
结果
该研究分析了 140 例 PsA 患者、51 例银屑病患者和 51 例 FMS 患者。在 PsA 组中进行了 1960 次和 1680 次临床和 US 检查，在银屑病组和 FMS 组中分别进行了 714 次和 612 次检查。在每位患者和每个附着点评估中，FMS 患者的附着点压痛频率更高（92%的患者和 46%的附着点，而 PsA 组为 66%/23%，银屑病组为 59%/18%）。通过 US 检查，在每位患者和每个附着点评估中，PsA 和银屑病患者的附着点受累征象更为常见（约 90%的 PsA 和银屑病组患者以及 75%的 FMS 组患者至少有 1 个部位受累，分别为 54%、41%和 27%的 PsA、银屑病和 FMS 患者的附着点对显示至少有 1 个附着点受累）。
结论
ULISSE 研究表明，如果仅进行临床检查，附着点炎是 PsA、银屑病和 FMS 患者的常见特征。US 附着点评估显示出与这 3 种疾病更一致的结果。
Zotero 插件